You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNabilone
Accession NumberDB00486  (APRD01127)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Nabilone is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It is a synthetic cannabinoid, which mimics the main ingredient of marijuana (THC) but it has more predictable side effects and causes no or minimal euphoria. Nabilone is not derived from the cannabis plant as is dronabinol.

In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.

Although it doesn’t have the official indication (except in Mexico), nabilone is widely used as an adjunct therapy for chronic pain management. Numerous trials and case studies have demonstrate various benefits for condition such as fibromyalgia and multiple scerosis.

Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers (“trans”).

Structure
Thumb
Synonyms
Cesamet
Nabilon
Nabilona
Nabilone
Nabilonum
External Identifiers
  • Cpd 109514
  • LY 109 514
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Nabilonecapsule0.5 mgoralActavis Pharma Company2012-10-02Not applicableCanada
Act Nabilonecapsule1 mgoralActavis Pharma Company2012-10-02Not applicableCanada
Cesametcapsule1 mg/1oralMeda Pharmaceuticals Inc.2010-03-01Not applicableUs
Cesametcapsule0.25 mgoralValeant Canada Lp Valeant Canada S.E.C.2008-09-12Not applicableCanada
Cesametcapsule0.5 mgoralValeant Canada Lp Valeant Canada S.E.C.2004-09-16Not applicableCanada
Cesametcapsule1 mgoralValeant Canada Lp Valeant Canada S.E.C.1982-12-31Not applicableCanada
Cesametcapsule1 mg/1oralValeant Pharmaceuticals North America2009-11-01Not applicableUs
PMS-nabilonecapsule0.25 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-nabilonecapsule1.0 mgoralPharmascience Inc2012-03-26Not applicableCanada
PMS-nabilonecapsule0.5 mgoralPharmascience Inc2012-03-26Not applicableCanada
Ran-nabilonecapsule0.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Ran-nabilonecapsule0.25 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Ran-nabilonecapsule1 mgoralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Teva-nabilonecapsule0.25 mgoralTeva Canada Limited2013-05-27Not applicableCanada
Teva-nabilonecapsule1.0 mgoralTeva Canada Limited2012-05-23Not applicableCanada
Teva-nabilonecapsule0.5 mgoralTeva Canada Limited2012-05-23Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nabilonecapsule0.25 mgoralApotex IncNot applicableNot applicableCanada
Apo-nabilonecapsule1 mgoralApotex IncNot applicableNot applicableCanada
Apo-nabilonecapsule0.5 mgoralApotex IncNot applicableNot applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NabiloneMeda
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2N4O9L084N
CAS number51022-71-0
WeightAverage: 372.5408
Monoisotopic: 372.266445018
Chemical FormulaC24H36O3
InChI KeyInChIKey=GECBBEABIDMGGL-RTBURBONSA-N
InChI
InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
IUPAC Name
(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6H,6aH,7H,8H,9H,10H,10aH-benzo[c]isochromen-9-one
SMILES
[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthopyranones. These are compounds containing a naphthopyran skeleton where a ring carbon bears a carboxylic acid group. Naphthtopyran is made up of the pyran ring fused to a naphthalene ring system.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthopyrans
Sub ClassNaphthopyranones
Direct ParentNaphthopyranones
Alternative Parents
Substituents
  • Naphthopyranone
  • 2,2-dimethyl-1-benzopyran
  • 1-benzopyran
  • Benzopyran
  • Chromane
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Cyclic ketone
  • Ketone
  • Oxacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed for the control of nausea and vomiting, caused by chemotherapeutic agents used in the treatment of cancer, in patients who have failed to respond adequately to conventional antiemetic treatments.
PharmacodynamicsNabilone is a cannabinoid with therapeutic uses. It is an analog of dronabinol (also known as tetrahydrocannabinol or THC), the psychoactive ingredient in cannabis. It is reserved for use in individuals who do not respond to the more commonly used anti-emetics. This is mainly because cannabinoids have potential adverse effects similar to that of cannabis and may cause changes in mood and behaviour.
Mechanism of actionThe mode of action of nabilone has been studied in cats and dogs. Although its anti-emetic action is not yet fully understood, it is apparent that there are a number of points in the control systems of the body at which Nabilone could block the emetic mechanism. It is likely that nabilone exerts its actions via binding to the cannabinoid receptors.
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract following oral administration.
Volume of distribution
  • 12.5 L/kg
Protein bindingNot Available
Metabolism

Hepatic. Two metabolic pathways have been suggested. The major pathway probably involves the direct oxidation of Nabilone to produce hydroxylic and carboxylic analogues. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted.

Route of eliminationThe route and rate of the elimination of nabilone and its metabolites are similar to those observed with other cannabinoids, including delta-9-THC (dronabinol). Therefore, it appears that the major excretory pathway is the biliary system.
Half life2 hours, with metabolites around 35 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include difficulty in breathing, hallucinations, mental changes (severe), nervousness or anxiety (severe). Monkeys treated with Nabilone at doses as high as 2mg/kg/day for a year experienced no significant adverse events. This result contrasts with the finding in a planned 1-year dog study that was prematurely terminated because of deaths associated with convulsions in dogs receiving as little as 0.5mg/kg/day. The earliest deaths, however, occurred at 56 days in dogs receiving 2mg/kg/day. The unusual vulnerability of the dog is not understood; it is hypothesised, however, that the explanation lies in the fact that the dog differs markedly from other species (including humans) in its metabolism of Nabilone.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9575
Caco-2 permeable+0.7787
P-glycoprotein substrateSubstrate0.8103
P-glycoprotein inhibitor INon-inhibitor0.7926
P-glycoprotein inhibitor IIInhibitor0.6054
Renal organic cation transporterNon-inhibitor0.836
CYP450 2C9 substrateNon-substrate0.7385
CYP450 2D6 substrateNon-substrate0.8433
CYP450 3A4 substrateSubstrate0.6842
CYP450 1A2 substrateNon-inhibitor0.6601
CYP450 2C9 inhibitorNon-inhibitor0.714
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.6521
CYP450 3A4 inhibitorNon-inhibitor0.8654
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7642
Ames testNon AMES toxic0.8337
CarcinogenicityNon-carcinogens0.8598
BiodegradationNot ready biodegradable0.9948
Rat acute toxicity2.5397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9159
hERG inhibition (predictor II)Non-inhibitor0.7654
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Meda pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral0.25 mg
Capsuleoral0.5 mg
Capsuleoral1 mg/1
Capsuleoral1 mg
Capsuleoral1.0 mg
Prices
Unit descriptionCostUnit
Cesamet 1 mg capsule13.99USD capsule
Cesamet 0.5 mg Capsule3.49USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000493 mg/mLALOGPS
logP7.5ALOGPS
logP6.36ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)9.33ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.2 m3·mol-1ChemAxon
Polarizability44.91 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB: A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol. 1988 Apr;24(4):685-9. [PubMed:2838294 ]
  2. Niiranen A, Mattson K: Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol. 1987 Aug;10(4):325-9. [PubMed:3039831 ]
  3. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979 Jun 7;300(23):1295-7. [PubMed:375088 ]
  4. Einhorn LH, Nagy C, Furnas B, Williams SD: Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep;21(8-9 Suppl):64S-69S. [PubMed:6271844 ]
External Links
ATC CodesA04AD11
AHFS Codes
  • 56:22.92
PDB EntriesNot Available
FDA labelDownload (94.9 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololNabilone may increase the tachycardic activities of Acebutolol.
AlfentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.
AlprazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.
AmitriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
AmobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
AmoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
AmphetamineNabilone may increase the tachycardic activities of Amphetamine.
AripiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
AsenapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Asenapine.
AzelastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenNabilone may increase the central nervous system depressant (CNS depressant) activities of Baclofen.
BenzphetamineNabilone may increase the tachycardic activities of Benzphetamine.
BrexpiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
BrimonidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
BromazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
BrompheniramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
BuprenorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
ButabarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
ButorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
CarbamazepineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbinoxamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
CarisoprodolNabilone may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
CetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.
ChlordiazepoxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
ChlorphenamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.
ChlorphentermineNabilone may increase the tachycardic activities of Chlorphentermine.
ChlorpromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
ChlorzoxazoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
ClemastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
ClenbuterolNabilone may increase the tachycardic activities of Clenbuterol.
ClobazamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
ClomipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
ClonazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.
ClonidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
ClorazepateNabilone may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
ClozapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
CocaineCocaine may increase the tachycardic activities of Nabilone.
CyclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
CyclobenzaprineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
CyproheptadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DantroleneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
DesfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
DesipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DesloratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
Dexchlorpheniramine maleateNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexchlorpheniramine maleate.
DiazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
DimenhydrinateNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DiphenhydramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.
DobutamineNabilone may increase the tachycardic activities of Dobutamine.
DopamineNabilone may increase the tachycardic activities of Dopamine.
DoxepinNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DoxylamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.
DroperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
EfavirenzNabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
EntacaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
EpinephrineNabilone may increase the tachycardic activities of Epinephrine.
EstazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
EszopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
EthanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthosuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
EthotoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
EzogabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.
FelbamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
FenoterolNabilone may increase the tachycardic activities of Fenoterol.
FentanylNabilone may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
FexofenadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.
FlibanserinNabilone may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
FlunarizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
FlupentixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.
FluphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
FlurazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
FormoterolNabilone may increase the tachycardic activities of Formoterol.
FosphenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
GabapentinNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
gabapentin enacarbilNabilone may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.
Gamma Hydroxybutyric AcidNabilone may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.
GuanfacineNabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
HaloperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
HydrocodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydromorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
HydroxyzineNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.
IloperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.
ImipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
IsofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.
IsoprenalineNabilone may increase the tachycardic activities of Isoprenaline.
KetamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
LabetalolNabilone may increase the tachycardic activities of Labetalol.
LamotrigineNabilone may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
LevetiracetamNabilone may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
LevocabastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.
LevocetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.
LevorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
LoratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loratadine.
LorazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
LoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
LurasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
MaprotilineNabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
MeclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Meclizine.
MephentermineNabilone may increase the tachycardic activities of Mephentermine.
MeprobamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
MetaraminolNabilone may increase the tachycardic activities of Metaraminol.
MetaxaloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
MethadoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethamphetamineNabilone may increase the tachycardic activities of Methamphetamine.
MethocarbamolNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
MethohexitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MethotrimeprazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethoxamineNabilone may increase the tachycardic activities of Methoxamine.
MethsuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
MidazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
MidodrineNabilone may increase the tachycardic activities of Midodrine.
MirtazapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.
NalbuphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
NaphazolineNabilone may increase the tachycardic activities of Naphazoline.
NitrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Nitrous oxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.
NorepinephrineNabilone may increase the tachycardic activities of Norepinephrine.
NortriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
OlanzapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
OlopatadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
OrciprenalineNabilone may increase the tachycardic activities of Orciprenaline.
OrphenadrineNabilone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
OxycodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.
OxymetazolineNabilone may increase the tachycardic activities of Oxymetazoline.
OxymorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
PaliperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
ParaldehydeNabilone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
PentazocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
PentobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
PerampanelNabilone may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
PerphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
PethidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PhenmetrazineNabilone may increase the tachycardic activities of Phenmetrazine.
PhenobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhentermineNabilone may increase the tachycardic activities of Phentermine.
PhenylephrineNabilone may increase the tachycardic activities of Phenylephrine.
PhenylpropanolamineNabilone may increase the tachycardic activities of Phenylpropanolamine.
PhenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
PimozideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
PipotiazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
PizotifenNabilone may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
PomalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
PregabalinNabilone may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
PrimidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Primidone.
ProchlorperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
ProcyclidineProcyclidine may increase the tachycardic activities of Nabilone.
PromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.
PromethazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
PropofolNabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.
ProtriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
QuazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
QuetiapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
RamelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
RemifentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
ReserpineNabilone may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
RisperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
RitodrineNabilone may increase the tachycardic activities of Ritodrine.
SalmeterolNabilone may increase the tachycardic activities of Salmeterol.
ScopolamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Scopolamine butylbromideNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine butylbromide.
SecobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
SevofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
Sodium oxybateNabilone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
StiripentolNabilone may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.
SufentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
SuvorexantNabilone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
TasimelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.
TemazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
TerbutalineNabilone may increase the tachycardic activities of Terbutaline.
TetrabenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.
ThalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
ThiothixeneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
TiagabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
TizanidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
TolcaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
TopiramateNabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
TramadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
TriazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
TrifluoperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
TrimipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
TriprolidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
VigabatrinNabilone may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.
ZaleplonNabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
ZiconotideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.
ZiprasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.
ZolpidemNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZonisamideNabilone may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
ZopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.
ZuclopenthixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Cannabinoid receptor activity
Specific Function:
Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis.
Gene Name:
CNR2
Uniprot ID:
P34972
Molecular Weight:
39680.275 Da
References
  1. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G: Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002 Jan;135(1):181-7. [PubMed:11786493 ]
  2. Mendizabal VE, Adler-Graschinsky E: Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol. 2007 Jun;151(4):427-40. Epub 2007 Apr 23. [PubMed:17450170 ]
  3. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494 ]
  4. Kraft B, Kress HG: [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz. 2004 Jun;18(3):203-10. [PubMed:15221424 ]
  5. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Drug binding
Specific Function:
Involved in cannabinoid-induced CNS effects. Acts by inhibiting adenylate cyclase. Could be a receptor for anandamide. Inhibits L-type Ca(2+) channel current. Isoform 2 and isoform 3 have altered ligand binding.
Gene Name:
CNR1
Uniprot ID:
P21554
Molecular Weight:
52857.365 Da
References
  1. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494 ]
  2. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062 ]
  3. Hirst RA, Almond SL, Lambert DG: Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci Lett. 1996 Dec 13;220(2):101-4. [PubMed:8981483 ]
  4. Pertwee RG: Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. [PubMed:10575283 ]
  5. Pertwee RG, Fernando SR: Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol. 1996 Aug;118(8):2053-8. [PubMed:8864542 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23